Fox Run Management L.L.C. purchased a new position in shares of Zai Lab Limited (NASDAQ:ZLAB - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 13,946 shares of the company's stock, valued at approximately $365,000.
Several other institutional investors also recently modified their holdings of the business. Janus Henderson Group PLC increased its stake in shares of Zai Lab by 34.2% during the 3rd quarter. Janus Henderson Group PLC now owns 8,760,074 shares of the company's stock worth $211,488,000 after purchasing an additional 2,232,507 shares during the last quarter. Wellington Management Group LLP grew its holdings in shares of Zai Lab by 18.4% during the third quarter. Wellington Management Group LLP now owns 8,436,606 shares of the company's stock worth $203,660,000 after purchasing an additional 1,312,115 shares in the last quarter. Bamco Inc. NY increased its holdings in shares of Zai Lab by 6.4% in the 3rd quarter. Bamco Inc. NY now owns 1,906,520 shares of the company's stock worth $46,023,000 after buying an additional 113,869 shares during the last quarter. Principal Financial Group Inc. purchased a new stake in Zai Lab during the fourth quarter valued at about $46,172,000. Finally, Allianz Asset Management GmbH lifted its position in Zai Lab by 188.6% in the 4th quarter. Allianz Asset Management GmbH now owns 1,505,866 shares of the company's stock worth $39,442,000 after buying an additional 984,041 shares during the last quarter. 41.65% of the stock is owned by institutional investors.
Insider Buying and Selling
In other news, CEO Ying Du sold 50,000 shares of the firm's stock in a transaction dated Friday, February 28th. The stock was sold at an average price of $34.47, for a total transaction of $1,723,500.00. Following the completion of the transaction, the chief executive officer now owns 494,117 shares in the company, valued at $17,032,212.99. This trade represents a 9.19 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Rafael Amado sold 3,000 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $38.41, for a total value of $115,230.00. Following the transaction, the insider now owns 30,834 shares of the company's stock, valued at $1,184,333.94. This represents a 8.87 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 125,127 shares of company stock valued at $4,139,672. 13.88% of the stock is owned by corporate insiders.
Zai Lab Trading Up 3.1 %
ZLAB stock traded up $1.11 on Friday, hitting $37.29. The company had a trading volume of 1,532,132 shares, compared to its average volume of 757,600. Zai Lab Limited has a 12-month low of $13.48 and a 12-month high of $39.77. The stock has a market cap of $4.09 billion, a price-to-earnings ratio of -13.46 and a beta of 1.08. The stock's 50-day simple moving average is $31.76 and its 200 day simple moving average is $28.25.
Zai Lab (NASDAQ:ZLAB - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported ($0.80) EPS for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.19). Zai Lab had a negative net margin of 76.14% and a negative return on equity of 36.97%. The business had revenue of $109.07 million for the quarter, compared to analysts' expectations of $110.15 million. Research analysts forecast that Zai Lab Limited will post -2.58 earnings per share for the current year.
Analysts Set New Price Targets
Several analysts have weighed in on ZLAB shares. Scotiabank began coverage on shares of Zai Lab in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $55.00 price target for the company. JPMorgan Chase & Co. raised their target price on Zai Lab from $44.00 to $51.00 and gave the company an "overweight" rating in a research note on Thursday, March 13th. Bank of America restated a "neutral" rating and issued a $36.10 price objective (up previously from $29.00) on shares of Zai Lab in a report on Monday, March 3rd. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Zai Lab in a report on Thursday.
View Our Latest Report on Zai Lab
Zai Lab Profile
(
Free Report)
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.
See Also
Before you consider Zai Lab, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zai Lab wasn't on the list.
While Zai Lab currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
